MCP
GSK icon

Martin Capital Partners’s GSK GSK Stock Holding History

Martin Capital Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-54,127
Closed -$2.49M – 71
2020
Q4 		$2.49M Sell
54,127
-21
-0% -$965 1.46% 37
2020
Q3 		$2.55M Sell
54,148
-729
-1% -$36.5K 1.7% 30
2020
Q2 		$2.8M Sell
54,877
-1,302
-2% -$66.8K 1.97% 26
2020
Q1 		$2.66M Sell
56,179
-988
-2% -$52.7K 2.03% 24
2019
Q4 		$3.36M Sell
57,167
-37,282
-39% -$2.07M 1.98% 27
2019
Q3 		$5.04M Buy
94,449
+2,091
+2% +$108K 3.39% 3
2019
Q2 		$4.62M Buy
92,358
+4,478
+5% +$225K 3.27% 5
2019
Q1 		$4.59M Buy
87,880
+12,676
+17% +$633K 3.54% 4
2018
Q4 		$3.59M Buy
75,204
+1,699
+2% +$83.7K 3.31% 7
2018
Q3 		$3.69M Buy
73,505
+1,840
+3% +$93.5K 3.31% 6
2018
Q2 		$3.61M Sell
71,665
-4,165
-5% -$210K 3.69% 3
2018
Q1 		$3.7M Buy
75,830
+5,274
+7% +$246K 3.69% 4
2017
Q4 		$3.13M Buy
+70,556
New +$3.26M 3.25% 12

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Martin Capital Partners's GSK Position: Q1 2021 in Review

Martin Capital Partners sold out of GSK (GSK) in Q1 2021, closing a stake of 54,127 shares — an estimated $2.49M sold.

Martin Capital Partners first reported a position in GSK in Q4 2017 and held it in 13 quarters. The position peaked at $5.04M in Q3 2019. 774 funds tracked by Wall St. Rank hold GSK as of Q1 2021.

  • Martin Capital Partners reported no remaining GSK position as of Q1 2021 after selling out during the quarter.
  • Martin Capital Partners sold 54,127 GSK shares in Q1 2021, an estimated $2.49M.
  • Martin Capital Partners first reported a position in GSK in Q4 2017 and held it in 13 quarters.
  • Martin Capital Partners's GSK position peaked at $5.04M in Q3 2019.
  • 774 funds tracked by Wall St. Rank held GSK as of Q1 2021.

Based on Martin Capital Partners's 13F filing for Q1 2021, filed 14 Apr 2021.